Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EP300 | Q09472 | 1/20 | 0.38 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.36 |
| ▸ | CDC25A | P30304 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.33 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.33 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CD81 | P60033 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2112671 | 1.00 | EP300 (0.38) | EP300TBXAS1CDC25AALDH1A1CYP3A4 | |
| SCHEMBL687330 | 0.98 | EP300 (0.35) | EP300TBXAS1CDC25AALDH1A1CYP3A4 | |
| SCHEMBL687328 | 0.98 | EP300 (0.35) | EP300TBXAS1CDC25AALDH1A1CYP3A4 | |
| SCHEMBL2114655 | 0.93 | CD81 (0.33) | EP300TBXAS1CDC25AALDH1A1CD81 | |
| SCHEMBL829915 | 0.85 | CD81 (0.35) | CD81BACE1 | |
| SCHEMBL5026154 | 0.85 | CD81 (0.35) | CD81BACE1 | |
| SCHEMBL22972968 | 0.84 | ALDH1A1 (0.48) | EP300TBXAS1ALDH1A1TSHRLPAR2 | |
| SCHEMBL4914974 | 0.83 | CD81 (0.31) | CD81 | |
| SCHEMBL523128 | 0.82 | ALDH1A1 (0.45) | EP300TBXAS1ALDH1A1TSHRCD81 | |
| SCHEMBL9487570 | 0.82 | ALDH1A1 (0.45) | EP300TBXAS1ALDH1A1TSHRCD81 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036808-B2 | Ink jet recording method using temporary curing radiation | SEIKO EPSON CORPORATION (JP) | 2024-07-16 | — | — | US | disclosed |
| EP-3460013-B1 | INK JET COMPOSITION SET AND INK JET RECORDING METHOD | SEIKO EPSON CORP (JP) | 2020-08-12 | — | — | EP | disclosed |
| US-10590297-B2 | Ink jet composition set and ink jet recording method | SEIKO EPSON CORPORATION (JP) | 2020-03-17 | — | — | US | disclosed |
| EP-3470477-A1 | RADIATION-CURABLE INK JET INK COMPOSITION AND INK JET RECORDING METHOD | Seiko Epson Corporation (JP) | 2019-04-17 | — | — | EP | disclosed |
| US-20190092957-A1 | INK JET COMPOSITION SET AND INK JET RECORDING METHOD | SEIKO EPSON CORPORATION (JP) | 2019-03-28 | — | — | US | disclosed |
| EP-3460013-A1 | INK JET COMPOSITION SET AND INK JET RECORDING METHOD | Seiko Epson Corporation (JP) | 2019-03-27 | — | — | EP | disclosed |
| US-9873808-B2 | Ultraviolet-curable ink jet ink composition | SEIKO EPSON CORPORATION (JP) | 2018-01-23 | — | — | US | disclosed |
| US-9827760-B2 | Ink jet recording method and ink jet recording apparatus | SEIKO EPSON CORPORATION (JP) | 2017-11-28 | — | — | US | disclosed |
| US-9796193-B2 | Ink jet recording method, ultraviolet curable ink and ink jet recording apparatus | SEIKO EPSON CORPORATION (JP) | 2017-10-24 | — | — | US | disclosed |
| US-9782982-B2 | Ink jet recording method, ultraviolet curable ink and ink jet recording apparatus | SEIKO EPSON CORPORATION (JP) | 2017-10-10 | — | — | US | disclosed |
| US-20120133059-A1 | RADIATION CURABLE INK JET COMPOSITION, RECORDED MATTER, AND INK JET RECORDING METHOD | SEIKO EPSON CORPORATION (JP) | 2012-05-31 | — | — | US | disclosed |
| US-8158214-B2 | Photocurable ink composition set, ink jet recording method, and recorded matter | SEIKO EPSON CORPORATION (JP) | 2012-04-17 | — | — | US | disclosed |
| US-20110195249-A1 | ADHESIVE COMPOSITION AND OPTICAL MEMBER | Wuxi Hengxin Optoelectronic Materials Co., Ltd. (CN) | 2011-08-11 | — | — | US | disclosed |
| US-20100310835-A1 | Coating Agent for Plastic Label, and Plastic Label | FUJI SEAL INTERNATIONAL, INC. (JP) | 2010-12-09 | — | — | US | disclosed |
| US-7763686-B2 | Having a narrow molecular weight distribution in a short amount of time and with good productivity by mixing a first Lewis acid with a proton source to generate initiator cations, and adding a vinyl ether and a second Lewis acid to initiate a high-speed polymerization | CANON KABUSHIKI KAISHA (JP) | 2010-07-27 | — | — | US | disclosed |
| US-20090041946-A1 | Photocuable Ink Composition Set, Ink Jet Recording Method, and Recorded Matter | SEIKO EPSON CORPORATION (JP) | 2009-02-12 | — | — | US | disclosed |
| US-7365106-B2 | Cationically curable composition for dental use | TOKUYAMA CORPORATION (JP) | 2008-04-29 | — | — | US | disclosed |
| US-20070049768-A1 | COMPOSITION OF VINYL ETHER GROUP CONTAINING (METH) ACRYLIC ACID ESTER AND PRODUCTION METHOD THEREOF | NIPPON SHOKUBAI CO., LTD. (JP) | 2007-03-01 | — | — | US | disclosed |
| US-20060194935-A1 | Process for producing polyalkenyl ether | CANON KABUSHIKI KAISHA (JP) | 2006-08-31 | — | — | US | disclosed |
| US-20050250868-A1 | Cationically curable composition for dental use | TOKUYAMA CORPORATION (JP) | 2005-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049768-A1 | COMPOSITION OF VINYL ETHER GROUP CONTAINING (METH) ACRYLIC ACID ESTER AND PRODUCTION METHOD THEREOF | MMAB, ME1, PRMT1 | EP300 1768/4885TBXAS1 4393/4885CDC25A 3721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.